• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Personalis Inc.

    2/27/25 5:27:26 PM ET
    $PSNL
    Medical Specialities
    Health Care
    Get the next $PSNL alert in real time by email
    S-8 1 d925869ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on February 27, 2025

    Registration No. 333-   

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    PERSONALIS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   27-5411038
    (State or other jurisdiction of
    Incorporation or organization)
      (I.R.S. Employer
    Identification No.)

    6600 Dumbarton Circle

    Fremont, California 94555

    (650) 752-1300

    (Address of principal executive offices) (Zip code)

    2019 Equity Incentive Plan

    2019 Employee Stock Purchase Plan

    (Full titles of the plans)

     

     

    Christopher Hall

    President and Chief Executive Officer

    Personalis, Inc.

    6600 Dumbarton Circle

    Fremont, California 94555

    (650) 752-1300

    (Name and address of agent for service) (Telephone number, including area code, of agent for service)

    Copies to:

     

    Laura Berezin

    Asa Henin

    Allison Peth
    Cooley LLP

    1700 Seventh Avenue

    Seattle, WA 98101-1355

    (206) 452-8700

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION E

    This Registration Statement on Form S-8 is being filed by the Registrant to register 4,258,557 additional shares of Common Stock reserved for issuance under the 2019 Plan and 500,000 additional shares of Common Stock reserved for issuance under the ESPP.

    Pursuant to General Instruction E of Form S-8, the contents of the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on June 20, 2019 (File No. 333-232233), the Registration Statement on Form S-8 filed with the Commission on March 25, 2020 (File No. 333-237386), the Registration Statement on Form S-8 filed with the Commission on May 7, 2020 (File No.  333-238080), the Registration Statement on Form S-8 filed with the Commission on February 25, 2021 (File No. 333-253528), the Registration Statement on Form S-8 filed with the Commission on February 24, 2022 (File No. 333-262998), the Registration Statement on Form S-8 filed with the Commission on February 23, 2023 (File No. 333-269971), the Registration Statement on Form S-8 filed with the Commission on May 15, 2023 (File No.  333-271940), and the Registration Statement on Form S-8 filed with the Commission on February 29, 2024 (File No. 333-277489) are hereby incorporated in this Registration Statement by reference to the extent not replaced hereby.

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS

    The information called for by Part I of Form S-8 is omitted from this Registration Statement in accordance with Rule 428 of the Securities Act, and the instructions to Form S-8. In accordance with the rules and regulations of the Commission and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3.

    Incorporation of Documents by Reference.

    The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:

    (a) The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on February 27, 2025.

    (b) The information specifically incorporated by reference into the Registrant’s Annual Report on Form 10-K for the year ended December  31, 2023 from the Registrant’s Definitive Proxy Statement on Schedule 14A filed with the Commission on April 2, 2024.

    (c) The description of the Registrant’s Common Stock filed as Exhibit 4.1 which is contained in a registration statement on Form 8-A filed on June 17, 2019 (File No.  001-38943) under the Exchange Act, including any amendment or report filed for the purpose of updating such description, including Exhibit 4.1 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Commission on February 25, 2021.

    (d) All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    1


    Item 8.

    Exhibits.

     

              Incorporation by Reference

    Exhibit

    Number

      

    Description

       Form    File No.    Exhibit    Filing Date
      4.1    Amended and Restated Certificate of Incorporation of Personalis, Inc.    8-K    001-38943    3.1    6/24/2019
      4.2    Amended and Restated Bylaws of Personalis, Inc.    8-K    001-38943    3.1    10/31/2022
      4.3    Form of common stock certificate of the Registrant.    S-1/A    333-231703    4.1    6/7/2019
      5.1*    Opinion of Cooley LLP.            
     23.1*    Consent of BDO USA, P.C. Independent Registered Public Accounting Firm.            
     23.2*    Consent of Cooley LLP (reference is made to Exhibit 5.1).            
     24.1*    Power of Attorney (reference is made to the signature page hereto).            
     99.1    Personalis, Inc. 2019 Equity Incentive Plan and forms of agreements thereunder.    S-1/A    333-231703    10.2    6/7/2019
     99.2    Personalis, Inc. 2019 Employee Stock Purchase Plan.    S-1/A    333-231703    10.3    6/7/2019
    107*    Filing Fee Table            

     

    *

    Filed herewith.

     

    2


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Fremont, State of California, on February 27, 2025.

     

    PERSONALIS, INC.
    By:   /s/ Aaron Tachibana
      Aaron Tachibana
      Chief Financial Officer and Chief Operating Officer
      (Principal Financial and Accounting Officer)

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Christopher Hall and Aaron Tachibana as his or her true and lawful attorneys-in-fact and agents, with the full power of substitution, for him or her and in their name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

     

    Name and Signature    Title   Date

    /s/ Christopher Hall

    Christopher Hall

      

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

      February 27, 2025

    /s/ Aaron Tachibana

    Aaron Tachibana

      

    Chief Financial Officer and Chief Operating Officer

    (Principal Financial and Accounting Officer)

      February 27, 2025

    /s/ Karin Eastham

    Karin Eastham

       Director   February 27, 2025

    /s/ Olivia Bloom

    Olivia Bloom

       Director   February 27, 2025

    /s/ A. Blaine Bowman

    A. Blaine Bowman

       Director   February 27, 2025

    /s/ Woodrow A. Myers, Jr.

    Woodrow A. Myers, Jr., M.D.

       Director   February 27, 2025

    /s/ Lonnie Shoff

    Lonnie Shoff

       Director   February 27, 2025

    /s/ Kenneth Widder

    Kenneth J. Widder, M.D.

       Director   February 27, 2025

     

     

    3

    Get the next $PSNL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PSNL

    DatePrice TargetRatingAnalyst
    12/2/2025$11.00Equal-Weight
    Morgan Stanley
    5/15/2025$6.00Buy
    Guggenheim
    3/17/2025$8.00Buy
    Canaccord Genuity
    2/6/2023$8.00Hold → Buy
    Needham
    2/6/2023Hold → Buy
    Needham
    2/25/2022$30.00 → $24.00Outperform
    Oppenheimer
    2/25/2022$30.00 → $18.00Buy
    Citigroup
    2/25/2022$50.00 → $38.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $PSNL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced the publication of a new study in npj Precision Oncology highlighting the power of its ultrasensitive molecular residual disease (MRD) assay, NeXT Personal®, in monitoring immunotherapy response across a broad range of advanced cancers. The study, titled "Ultrasensitive ctDNA monitoring reveals early predictors of immunotherapy response in advanced cancer," was led by oncology researchers at UC San Diego Moores Cancer Center. The findings reinforce the NeXT Personal test's ability to detect circulating tumor DNA (ctDNA) at ultrasensitive levels, providing a window for earlier clinical i

    2/2/26 6:00:00 AM ET
    $PSNL
    Medical Specialities
    Health Care

    Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 at the Cliff Lodge in Snowbird, UT. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over

    1/28/26 4:01:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™

    New NeXT Personal® extension empowers clinicians to identify emerging resistance and therapeutically targetable mutations during disease monitoring and surveillance Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today announced the early access launch of Real-Time Variant Tracker, a powerful new option added to its ultrasensitive NeXT Personal molecular residual disease (MRD) test designed to detect small traces of circulating tumor DNA (ctDNA) in the blood that represent residual or recurrent cancer. Clinicians using the NeXT Personal MRD test will now be able to opt-in for additional reporting on detected resistance and therapeutically targetable mutations t

    1/12/26 4:00:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    $PSNL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley resumed coverage on Personalis with a new price target

    Morgan Stanley resumed coverage of Personalis with a rating of Equal-Weight and set a new price target of $11.00

    12/2/25 8:29:48 AM ET
    $PSNL
    Medical Specialities
    Health Care

    Guggenheim initiated coverage on Personalis with a new price target

    Guggenheim initiated coverage of Personalis with a rating of Buy and set a new price target of $6.00

    5/15/25 8:13:23 AM ET
    $PSNL
    Medical Specialities
    Health Care

    Canaccord Genuity initiated coverage on Personalis with a new price target

    Canaccord Genuity initiated coverage of Personalis with a rating of Buy and set a new price target of $8.00

    3/17/25 8:20:27 AM ET
    $PSNL
    Medical Specialities
    Health Care

    $PSNL
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Personalis Inc.

    SCHEDULE 13G/A - Personalis, Inc. (0001527753) (Subject)

    1/29/26 8:35:47 PM ET
    $PSNL
    Medical Specialities
    Health Care

    SEC Form 144 filed by Personalis Inc.

    144 - Personalis, Inc. (0001527753) (Subject)

    1/22/26 4:34:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    Personalis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Personalis, Inc. (0001527753) (Filer)

    1/8/26 8:05:26 AM ET
    $PSNL
    Medical Specialities
    Health Care

    $PSNL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Myers Woodrow A Jr bought $16,700 worth of shares (10,000 units at $1.67), increasing direct ownership by 62% to 26,116 units (SEC Form 4)

    4 - Personalis, Inc. (0001527753) (Issuer)

    3/5/24 5:15:53 PM ET
    $PSNL
    Medical Specialities
    Health Care

    $PSNL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO AND COO Tachibana Aaron exercised 1,201 shares at a strike of $9.16 and sold $13,812 worth of shares (1,201 units at $11.50) (SEC Form 4)

    4 - Personalis, Inc. (0001527753) (Issuer)

    1/23/26 6:03:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    CFO AND COO Tachibana Aaron exercised 103,668 shares at a strike of $9.16 and sold $1,117,541 worth of shares (103,668 units at $10.78) (SEC Form 4)

    4 - Personalis, Inc. (0001527753) (Issuer)

    11/28/25 5:09:45 PM ET
    $PSNL
    Medical Specialities
    Health Care

    PRESIDENT AND CEO Hall Christopher M sold $266,212 worth of shares (29,612 units at $8.99), decreasing direct ownership by 17% to 148,486 units (SEC Form 4)

    4 - Personalis, Inc. (0001527753) (Issuer)

    11/5/25 4:05:09 PM ET
    $PSNL
    Medical Specialities
    Health Care

    $PSNL
    Leadership Updates

    Live Leadership Updates

    View All

    Personalis Appoints Former Roche Diagnostics and GRAIL Executive Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance

    Bhandari to drive regulatory strategies for minimal residual disease (MRD) cancer test Personalis achieves ISO 13485:2016 certification, attesting to its ability to deliver medical devices and related services of the highest quality Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomic testing for precision oncology, today announced the appointment of Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance. With over two decades of industry marketing and regulatory affairs experience, Ms. Bhandari will help the company navigate the regulatory requirements for the NeXT Personal® MRD test. She was most recently VP, Regulatory Affairs at GRAIL, and previously held se

    10/18/23 7:15:00 AM ET
    $PSNL
    Medical Specialities
    Health Care

    Dr. Kenneth J. Widder Joins Personalis Board of Directors

    Personalis, Inc. (NASDAQ:PSNL) today announced that it has appointed Kenneth J. Widder, M.D., to its Board of Directors. Dr. Widder currently serves on the boards of QuidelOrtho Corporation and Evoke Pharma, Inc. and has over 40 years of experience working with biomedical companies, having previously served as a founder, director and/or CEO of Sydnexis, Inc., OrphoMed, Inc., Sytera, Inc., NovaCardia, Inc., Santarus, Inc., and Molecular Biosystems Inc., and as a general partner at LVP Life Science Ventures (formerly Latterell Venture Partners) and Windamere Venture Partners. He holds an M.D. from Northwestern University and trained in pathology at Duke University. "We are delighted to ha

    6/13/23 7:01:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    Personalis Announces CEO Retirement and Transition

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced that John West, co-founder, CEO and member of the board of directors of Personalis, notified the Company of his decision to retire as CEO and a director at the end of the calendar year. Mr. West has served in the DNA sequencing field for over forty years, and co-founded Personalis with four Stanford professors in 2011. Effective December 31, 2022, Aaron Tachibana, Personalis Chief Financial Officer, will serve as interim CEO and Christopher Hall, Personalis SVP and Head, Diagnostics Business, will be promoted to President. Mr. West will continue to serve as an advisor to the Board. "We th

    12/14/22 4:02:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    $PSNL
    Financials

    Live finance-specific insights

    View All

    Personalis Reports Third Quarter 2025 Financial Results

    Company Advances "Win-in-MRD" Strategy with Compelling Clinical Trial Data and Increasing Physician Adoption of NeXT Personal® Platform Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2025. The quarter was distinguished by significant operational momentum in its "Win-in-MRD" strategy, headlined by increasing clinical tests delivered and robust clinical evidence generation. Third Quarter 2025 and Recent Business Highlights Accelerated Clinical Adoption: Delivered 4,388 clinical tests, demonstrating robust 26% sequential increase over Q2 2025 and a 364% year-over-year growth fu

    11/4/25 4:01:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    Personalis to Announce Third Quarter 2025 Financial Results

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its third quarter 2025 financial results on Tuesday, November 4, 2025. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The live webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shor

    10/21/25 4:01:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    Personalis Reports Second Quarter 2025 Financial Results

    Strong Q2 Clinical Momentum with 59% Sequential Growth in Test Volume Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2025, and recent accomplishments of its "Win-in-MRD" strategy: Second Quarter 2025 and Recent Business Highlights Clinical Adoption Acceleration: Delivered 3,478 clinical tests in the second quarter, a 59% sequential increase over Q1 2025, demonstrating accelerating physician adoption of the NeXT Personal® platform Commercial Partnership Expansion: Broadened the strategic collaboration with Tempus AI, Inc. (Tempus) to add colorectal cancer, a major new indic

    8/5/25 4:01:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    $PSNL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Personalis Inc.

    SC 13G/A - Personalis, Inc. (0001527753) (Subject)

    8/19/24 6:03:38 AM ET
    $PSNL
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Personalis Inc.

    SC 13G - Personalis, Inc. (0001527753) (Subject)

    7/26/24 12:56:21 PM ET
    $PSNL
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13D/A filed by Personalis Inc.

    SC 13D/A - Personalis, Inc. (0001527753) (Subject)

    6/28/24 4:01:17 PM ET
    $PSNL
    Medical Specialities
    Health Care